hydrochlorothiazide has been researched along with Fatty Liver, Nonalcoholic in 2 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic steatohepatitis is a common finding in patients with CVD." | 2.80 | PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. ( Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merat, S | 2 |
| Jafari, E | 2 |
| Radmard, AR | 2 |
| Khoshnia, M | 2 |
| Sharafkhah, M | 1 |
| Nateghi Baygi, A | 1 |
| Marshall, T | 2 |
| Shiravi Khuzani, A | 2 |
| Cheng, KK | 1 |
| Poustchi, H | 2 |
| Malekzadeh, R | 2 |
| Hemming, K | 1 |
| Nateghi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.[NCT01245608] | Phase 3 | 2,400 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for hydrochlorothiazide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; No | 2022 |
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; | 2015 |